Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Alec C. Kimmelman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0002-9465-8411; OpenAlex author ID A5011348783; NIH RePORTER profile ID 8586116. Sources: funder_awards.

Their work

Papers
46 (first author 6, last author 17)
Trials
0
Grants
4
Labs led
2
Collaborators
177
Papers, trials and grants by year

2010: 1 grant · 2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 7 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 4 papers, 2 grants · 2019: 2 papers · 2020: 6 papers · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 3 papers, 1 grant · 2025: 2 papers · 2026: 5 papers

Papers 46

  1. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  2. Hepatocytes promote liver metastasis of pancreatic cancer by providing serine. Last author DOI 10.1038/s41586-026-11051-z↗
  3. Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis. Co-author DOI 10.1126/sciadv.adz8681↗
  4. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
  5. Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells. Last author DOI 10.1158/0008-5472.can-25-2451↗
  6. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  7. Genetics and biology of pancreatic ductal adenocarcinoma. First author DOI 10.1101/gad.351863.124↗
  8. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Last author DOI 10.1038/s43018-023-00647-3↗
  9. Autophagy fuels mitochondrial function through regulation of iron metabolism in pancreatic cancer. Last author DOI 10.1080/15548627.2023.2223473↗
  10. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  11. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  12. Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer. Last author DOI 10.1126/sciadv.adf9284↗
  13. Metabolic reprogramming of tumor-associated macrophages by collagen turnover promotes fibrosis in pancreatic cancer. Co-author DOI 10.1073/pnas.2119168119↗
  14. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  15. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  16. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. Co-author DOI 10.1200/op.22.00088↗
  17. Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. Last author DOI 10.1016/j.cmet.2020.10.018↗
  18. Autophagy is required for proper cysteine homeostasis in pancreatic cancer through regulation of SLC7A11. Last author DOI 10.1073/pnas.2021475118↗
  19. Autophagy is critical for cysteine metabolism in pancreatic cancer through regulation of SLC7A11. First author DOI 10.1080/15548627.2021.1922984↗
  20. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. Co-author DOI 10.1101/gad.348787.121↗
  21. Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. Last author DOI 10.1016/j.cell.2020.10.016↗
  22. Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer. Last author DOI 10.1016/j.celrep.2020.108231↗
  23. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Last author DOI 10.1038/s41586-020-2229-5↗
  24. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  25. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. Last author DOI 10.1080/15548627.2020.1769973↗
  26. Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-19-0959↗
  27. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Co-author DOI 10.1038/s41588-019-0475-y↗
  28. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  29. The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. First author DOI 10.1016/j.bbcan.2018.04.011↗
  30. Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bmcl.2018.04.061↗
  31. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Last author DOI 10.1038/s41467-018-07472-8↗
  32. Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. Last author DOI 10.1158/2159-8290.cd-17-0952↗
  33. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Co-author DOI 10.1073/pnas.1620164114↗
  34. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv409↗
  35. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Co-author DOI 10.1186/s40170-015-0137-1↗
  36. KRAS: feeding pancreatic cancer proliferation. Co-author DOI 10.1016/j.tibs.2013.12.004↗
  37. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗
  38. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Co-author DOI 10.1038/nm.3686↗
  39. The complex landscape of pancreatic cancer metabolism. First author DOI 10.1093/carcin/bgu097↗
  40. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Last author DOI 10.1634/theoncologist.2014-0086↗
  41. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Co-author DOI 10.4161/21624011.2014.970914↗
  42. Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 status. First author DOI 10.4161/auto.29961↗
  43. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Last author DOI 10.1038/nature12040↗
  44. Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. Last author DOI 10.1371/journal.pone.0039588↗
  45. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Co-author DOI 10.1158/2159-8290.cd-11-0031↗
  46. A critical role for autophagy in pancreatic cancer. First author DOI 10.4161/auto.7.8.15762↗

Grants 4

  1. Identifying Metabolic Dependencies of Pancreatic Cancers R35CA232124↗
  2. Investigating the Role of Autophagy in Pancreatic Cancer Radiation Resistance R01CA157490↗
  3. Investigating a novel glutamine metabolism pathway in pancreatic cancer R01CA188048↗
  4. DNA Repair and the DNA Damage Response in Pancreatic Cancer AWARD pancan:2010-alec-kimmelman-md-phd-dna-repair-and-the-dna-damage-response-i

Closest collaborators

The 25 strongest of 177 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas E. Biancur · 10 shared papers, 2018–2026 · strength 1.62
  2. Joel Encarnación-Rosado · 7 shared papers, 2020–2026 · strength 1.45
  3. Subhadip Mukhopadhyay · 6 shared papers, 2020–2026 · strength 1.34
  4. Elaine Y. Lin · 7 shared papers, 2018–2026 · strength 1.29
  5. Keisuke Yamamoto · 8 shared papers, 2020–2026 · strength 1.17
  6. Joseph Douglas Mancias · 8 shared papers, 2014–2023 · strength 0.86
  7. Haoqiang Ying · 8 shared papers, 2011–2026 · strength 0.80
  8. Seth J. Parker · 5 shared papers, 2020–2024 · strength 0.71
  9. Ronald Anthony Depinho · 6 shared papers, 2011–2026 · strength 0.69
  10. Robert Singhung Banh · 5 shared papers, 2020–2026 · strength 0.68
  11. Costas Andreas Lyssiotis · 8 shared papers, 2013–2026 · strength 0.60
  12. Dafna Bar‐Sagi · 3 shared papers, 2020–2026 · strength 0.51
  13. Peter Y. Yu · 2 shared papers, 2026 · strength 0.50
  14. Mohamad Assi · 2 shared papers, 2026 · strength 0.50
  15. David Tsai Ting · 4 shared papers, 2022–2024 · strength 0.48
  16. David P. Ryan · 4 shared papers, 2022–2024 · strength 0.48
  17. Richard Possemato · 2 shared papers, 2026 · strength 0.47
  18. Huamin Wang · 4 shared papers, 2014–2026 · strength 0.42
  19. Lewis C. Cantley · 5 shared papers, 2013–2026 · strength 0.38
  20. João A. Paulo · 4 shared papers, 2019–2021 · strength 0.38
  21. Jin Peng He · 3 shared papers, 2022–2024 · strength 0.36
  22. Toni T. Seppälä · 3 shared papers, 2022–2024 · strength 0.36
  23. Richard Andrew Burkhart · 3 shared papers, 2022–2024 · strength 0.36
  24. Christopher L. Wolfgang · 3 shared papers, 2022–2024 · strength 0.36
  25. Reecha Suri · 3 shared papers, 2022–2024 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.